Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH

Designation highlights EFX's potential to treat NASH and its related comorbidities SOUTH SAN FRANCISCO, Calif., Oct. 16, 2020 -- (Healthcare Sales & Marketing Network) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatoh... Biopharmaceuticals, Mergers & Acquisitions Akero Therapeutics, non-alcoholic steatohepatitis, efruxifermin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news